Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post- Marketing, Prospective,Multicenter, Observational Program: Severity of Bleeding as a Predictor of Quality of Life (QoL) in Women With Heavy Menstrual Bleeding (HMB) Under Dydrogesterone Treatment

NCT01647360 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT01647360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01647360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post- Marketing, Prospective,Multicenter, Observational Program: Severity of Bleeding as a Predictor of Quality of Life (QoL) in Women With Heavy Menstrual Bleeding (HMB) Under Dydrogesterone Treatment
Lead sponsor
Abbott
Phase
Observational
Overall status
Completed
Start date
June 30, 2012
Completion date
May 31, 2013
Enrollment
210 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

menorrhagia, metrorrhagia